Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Green Kevin Dennis | Chief Financial Officer | May 10 | Sale | 4.98 | 57,335 | 285,373 | 222,999 | May 12 06:36 PM | Jayaraman Vivek K | Chief Operating Officer | Mar 14 | Sale | 5.04 | 41,734 | 210,320 | 327,097 | Mar 15 09:59 PM | Greenman William Mariner | President and CEO | Mar 14 | Sale | 5.04 | 165,021 | 831,634 | 1,885,141 | Mar 15 10:00 PM | CORASH LAURENCE M | Chief Scientific Officer | Mar 14 | Sale | 5.04 | 30,307 | 152,735 | 2,101,434 | Mar 15 09:57 PM | Green Kevin Dennis | Chief Financial Officer | Mar 14 | Sale | 5.04 | 32,102 | 161,780 | 251,847 | Mar 15 09:55 PM | Benjamin Richard J | Chief Medical Officer | Mar 14 | Sale | 5.04 | 30,307 | 152,735 | 157,383 | Mar 15 09:50 PM | Moore Carol | SVP Reg. & Quality | Mar 14 | Sale | 5.04 | 28,513 | 143,695 | 257,192 | Mar 16 06:29 PM | Menard Chrystal | Chief Legal Officer | Mar 14 | Sale | 5.04 | 30,307 | 152,734 | 149,589 | Mar 16 06:25 PM | Greenman William Mariner | President and CEO | Feb 25 | Option Exercise | 3.75 | 380,000 | 1,425,000 | 1,902,281 | Mar 01 09:18 PM | Greenman William Mariner | President and CEO | Feb 25 | Sale | 5.70 | 308,263 | 1,757,043 | 1,594,018 | Mar 01 09:18 PM | Moore Carol | SVP Reg. & Quality | Jan 03 | Option Exercise | 3.66 | 19,059 | 69,756 | 200,335 | Jan 05 07:24 PM | Moore Carol | SVP Reg. & Quality | Jan 03 | Sale | 7.00 | 19,059 | 133,417 | 181,276 | Jan 05 07:24 PM | CORASH LAURENCE M | Chief Scientific Officer | Dec 17 | Option Exercise | 3.75 | 5,000 | 18,750 | 2,027,586 | Dec 21 05:29 PM | CORASH LAURENCE M | Chief Scientific Officer | Dec 13 | Option Exercise | 3.75 | 40,000 | 150,000 | 2,022,586 | Dec 15 08:57 PM | SCHULZE GAIL | Director | Nov 09 | Option Exercise | 2.86 | 25,000 | 71,500 | 53,116 | Nov 09 08:43 PM | SCHULZE GAIL | Director | Nov 09 | Sale | 7.54 | 25,000 | 188,430 | 28,116 | Nov 09 08:43 PM | Moore Carol | SVP Reg. & Quality | Nov 05 | Option Exercise | 3.75 | 110,000 | 412,500 | 289,555 | Nov 09 08:38 PM | Moore Carol | SVP Reg. & Quality | Nov 05 | Sale | 7.94 | 110,000 | 873,191 | 181,276 | Nov 09 08:38 PM | Benjamin Richard J | Chief Medical Officer | Nov 03 | Option Exercise | 4.56 | 165,000 | 753,133 | 176,035 | Nov 05 07:41 PM | Green Kevin Dennis | Chief Financial Officer | Nov 03 | Option Exercise | 3.75 | 95,000 | 356,250 | 248,740 | Nov 05 07:47 PM | Menard Chrystal | Chief Legal Officer | Nov 03 | Sale | 7.70 | 40,000 | 308,000 | 67,038 | Nov 05 07:51 PM | Green Kevin Dennis | Chief Financial Officer | Nov 03 | Sale | 7.00 | 95,741 | 670,187 | 152,999 | Nov 05 07:47 PM | Benjamin Richard J | Chief Medical Officer | Nov 03 | Sale | 7.68 | 165,000 | 1,267,750 | 76,035 | Nov 05 07:41 PM | Swisher Daniel N JR | Director | Aug 04 | Option Exercise | 2.86 | 12,877 | 36,828 | 106,231 | Aug 05 05:08 PM | Swisher Daniel N JR | Director | Aug 04 | Sale | 6.25 | 12,877 | 80,481 | 93,354 | Aug 05 05:08 PM | Greenman William Mariner | President and CEO | Aug 03 | Option Exercise | 2.08 | 100,000 | 208,000 | 1,518,672 | Aug 05 05:12 PM |
|